Currently, there are 184.46M common shares owned by the public and among those 177.74M shares have been available to trade.
The company’s stock has a 5-day price change of -13.46% and -49.64% over the past three months. NKTR shares are trading -24.73% year to date (YTD), with the 12-month market performance up to 4.48% higher. It has a 12-month low price of $0.63 and touched a high of $1.93 over the same period. NKTR has an average intraday trading volume of 1.78 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -16.70%, -26.32%, and -43.11% respectively.
Institutional ownership of Nektar Therapeutics (NASDAQ: NKTR) shares accounts for 74.29% of the company’s 184.46M shares outstanding.
It has a market capitalization of $129.12M and a beta (3y monthly) value of 0.68. The earnings-per-share (ttm) stands at -$0.84. Price movements for the stock have been influenced by the stock’s volatility, which stands at 9.12% over the week and 7.73% over the month.
Earnings per share for the fiscal year are expected to increase by 50.60%, and -6.97% over the next financial year.
Looking at the support for the NKTR, a number of firms have released research notes about the stock. B. Riley Securities stated their Buy rating for the stock in a research note on January 08, 2025, with the firm’s price target at $4. H.C. Wainwright coverage for the Nektar Therapeutics (NKTR) stock in a research note released on December 10, 2024 offered a Buy rating with a price target of $6.50. Piper Sandler was of a view on November 04, 2024 that the stock is Overweight, while BTIG Research gave the stock Buy rating on September 30, 2024, issuing a price target of $4. Rodman & Renshaw on their part issued Buy rating on June 28, 2024.
